

nextgen oncology
where better outcomes matter most

"nextgen" is a fully automated practice with great efficiency gains and better patient outcomes
The challenges of full digitization are often underestimated. The overall concept is usually missing, so that the efficiency gained in individual areas can be lost again at the interfaces.
Innovative
software
From digitized guidelines, to AI-supported therapy plans, and to all interfaces
Therapy-
security
All steps flow seamlessly into one another via the same software platform
Process-
optimization
From relief by specialized onco-nurses to digital documentation to networks with all partners
Quality
management
From regulations to ISO certification to outcome measurement


Oncology in Transition.
Big Challenges.
The term “ nextgen ” is primarily used by software companies. Until now, software was a fixed set of instructions (code). The new generation of software, on the other hand, is dynamic in that it learns from results (machine learning) and thus develops into a so-called “AI”, artificial intelligence .
​
It has become a matter of course for every doctor to use software as an important tool and there are excellent programs specialized for doctors. KImed builds on this and reaches a new level in two ways:
​
-
The full integration of all practice processes based on a single software architecture enables previously unattainable efficiency.
-
In academic cooperation, we are developing self-learning algorithms that provide medical staff with decision support tools from the flood of data. This leads to better outcomes.
Our progress:
5
Cooperatiion Partners
600+
Digitized therapy plans
2
Locations
2
Federal States
coming
​
Certifications


Are You Ready to Achieve Better Outcomes?
From pharmaceuticals we know that ​ 90% of the drugs only work in 50% of the patients.
The situation is similar with cancer therapies.
The biotech revolution has begun, but only the efficient evaluation and channelling of data will lead to better results.
​
“ We are at the beginning of the revolution to more precise medicine ”, CEO of a leading biotech company